PMID- 30201375
OWN - NLM
STAT- MEDLINE
DCOM- 20190128
LR  - 20190128
IS  - 1879-0712 (Electronic)
IS  - 0014-2999 (Linking)
VI  - 838
DP  - 2018 Nov 5
TI  - Inhibition of alpha2C-adrenoceptors ameliorates cisplatin-induced acute renal failure 
      in rats.
PG  - 113-119
LID - S0014-2999(18)30528-4 [pii]
LID - 10.1016/j.ejphar.2018.09.010 [doi]
AB  - Nephrotoxicity is a major adverse reaction of the anticancer drug, cisplatin. We 
      investigated the renoprotective effects of the alpha2-adrenoceptor antagonist, 
      yohimbine and selective alpha2C-adrenoceptor antagonist, JP-1302, in 
      cisplatin-treated Sprague Dawley rats. Rats were given a single intravenous dose 
      of 7.5 mg/kg cisplatin and then yohimbine or JP-1302 was administered 
      intraperitoneally at 0.1 or 3 mg/kg/day, respectively, for four days. Renal 
      functional parameters, such as blood urea nitrogen, plasma creatinine, creatinine 
      clearance and renal venous norepinephrine concentrations were measured. Kidney 
      tissue damage and tumour necrosis factor-alpha (TNF-alpha) and monocyte chemoattractant 
      protein-1 (MCP-1) mRNA levels were assessed after the animals were euthanized. 
      Cisplatin treatment aggravated the kidney functional parameters of blood urea 
      nitrogen, plasma creatinine and creatinine clearance. Renal venous norepinephrine 
      concentrations were also elevated after cisplatin administration. Treatment with 
      yohimbine or JP-1302 clearly ameliorated kidney function and cell apoptosis. 
      These treatments suppressed elevated renal plasma norepinephrine, TNF-alpha, MCP-1 
      and cleaved caspase 3 expressions which occurred after administration of 
      cisplatin. These results suggest that yohimbine can prevent cisplatin-induced 
      renal toxicity associated with acute kidney injury by suppressing cytokine 
      expression through alpha2C-adrenoceptors.
CI  - Copyright (c) 2018 Elsevier B.V. All rights reserved.
FAU - Tsutsui, Hidenobu
AU  - Tsutsui H
AD  - Laboratory of Clinical Pharmacology, Faculty of Pharmacy, Osaka Ohtani 
      University, 3-11-1 Nishikiori-kita, Tondabayashi, Osaka 584-8540, Japan.
FAU - Shimokawa, Takaomi
AU  - Shimokawa T
AD  - Laboratory of Clinical Pharmacology, Faculty of Pharmacy, Osaka Ohtani 
      University, 3-11-1 Nishikiori-kita, Tondabayashi, Osaka 584-8540, Japan. 
      Electronic address: simokataka@osaka-ohtani.ac.jp.
FAU - Miura, Takeshi
AU  - Miura T
AD  - Pharmaceutical Education Support Center, School of Pharmacy and Pharmaceutical 
      Sciences, Mukogawa Women's University, 9-11-68 Koshien, Nishinomiya, Hyogo 
      663-8179, Japan.
FAU - Takama, Masashi
AU  - Takama M
AD  - Laboratory of Pharmaceutics, Faculty of Pharmacy, Osaka Ohtani University, 3-11-1 
      Nishikiori-kita, Tondabayashi, Osaka 584-8540, Japan.
FAU - Nishinaka, Toru
AU  - Nishinaka T
AD  - Laboratory of Biochemistry, Faculty of Pharmacy, Osaka Ohtani University, 3-11-1 
      Nishikiori-kita, Tondabayashi, Osaka 584-8540, Japan.
FAU - Terada, Tomoyuki
AU  - Terada T
AD  - Laboratory of Biochemistry, Faculty of Pharmacy, Osaka Ohtani University, 3-11-1 
      Nishikiori-kita, Tondabayashi, Osaka 584-8540, Japan.
FAU - Yamagata, Masayo
AU  - Yamagata M
AD  - Laboratory of Clinical Pharmacology, Faculty of Pharmacy, Osaka Ohtani 
      University, 3-11-1 Nishikiori-kita, Tondabayashi, Osaka 584-8540, Japan.
FAU - Yukimura, Tokihito
AU  - Yukimura T
AD  - Laboratory of Clinical Pharmacology, Faculty of Pharmacy, Osaka Ohtani 
      University, 3-11-1 Nishikiori-kita, Tondabayashi, Osaka 584-8540, Japan.
LA  - eng
PT  - Journal Article
DEP - 20180907
PL  - Netherlands
TA  - Eur J Pharmacol
JT  - European journal of pharmacology
JID - 1254354
RN  - 0 (Acridines)
RN  - 0 (Adra2c protein, rat)
RN  - 0 (Adrenergic alpha-2 Receptor Antagonists)
RN  - 0 (Ccl2 protein, rat)
RN  - 0 (Chemokine CCL2)
RN  - 0 (JP-1302)
RN  - 0 (Piperazines)
RN  - 0 (Receptors, Adrenergic, alpha-2)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 2Y49VWD90Q (Yohimbine)
RN  - Q20Q21Q62J (Cisplatin)
RN  - X4W3ENH1CV (Norepinephrine)
SB  - IM
MH  - Acridines/*pharmacology/therapeutic use
MH  - Acute Kidney Injury/blood/chemically induced/*drug therapy/pathology
MH  - Adrenergic alpha-2 Receptor Antagonists/*pharmacology/therapeutic use
MH  - Animals
MH  - Apoptosis/drug effects
MH  - Chemokine CCL2/metabolism
MH  - Cisplatin/*adverse effects
MH  - Disease Models, Animal
MH  - Injections, Intraperitoneal
MH  - Kidney/drug effects/pathology
MH  - Male
MH  - Norepinephrine/blood
MH  - Piperazines/*pharmacology/therapeutic use
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Receptors, Adrenergic, alpha-2/metabolism
MH  - Tumor Necrosis Factor-alpha/metabolism
MH  - Yohimbine/*pharmacology/therapeutic use
OTO - NOTNLM
OT  - Acute kidney injury
OT  - Cisplatin
OT  - Nephrotoxicity
OT  - Yohimbine
EDAT- 2018/09/12 06:00
MHDA- 2019/01/29 06:00
CRDT- 2018/09/12 06:00
PHST- 2018/05/11 00:00 [received]
PHST- 2018/09/05 00:00 [revised]
PHST- 2018/09/05 00:00 [accepted]
PHST- 2018/09/12 06:00 [pubmed]
PHST- 2019/01/29 06:00 [medline]
PHST- 2018/09/12 06:00 [entrez]
AID - S0014-2999(18)30528-4 [pii]
AID - 10.1016/j.ejphar.2018.09.010 [doi]
PST - ppublish
SO  - Eur J Pharmacol. 2018 Nov 5;838:113-119. doi: 10.1016/j.ejphar.2018.09.010. Epub 
      2018 Sep 7.